All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Camidanlumab tesirine
Therapeutic Area: Oncology Product Name: ADCT-301
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: ADC Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 30, 2020
Details:
The parties have agreed to eliminate the defined divestment process which was agreed in 2013 and that envisaged, among other things, offering the opportunity for third parties to continue the development and commercialization of Cami.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SCO-101,Taxane
Therapeutic Area: Oncology Product Name: SCO-101
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
The company has received final approval from the Danish Medicines Agency and Ethical Committee to initiate a clinical trial with the drug candidate SCO-101 in combination with first line chemotherapy in patients with inoperable or metastatic pancreatic cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tisotumab Vedotin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
Results from the phase 2 innovaTV 204 study evaluating tisotumab vedotin in patients with recurrent or metastatic cervical cancer will be presented as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 2X-121
Therapeutic Area: Oncology Product Name: 2X-121
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: 2X Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 13, 2020
Details:
The Company now has 100 % ownership of 2X-121, which is being clinically developed as an anti-cancer therapeutic, as well as being tested as an anti-viral agent against COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tisotumab Vedotin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2020
Details:
Results from innovaTV 204 evaluating tisotumab vedotin showed that a 24 percent confirmed objective response rate (ORR) by independent central review (95% Confidence Interval: 15.9% - 33.3%) with a median duration of response (DOR) of 8.3 months.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cisplatin
Therapeutic Area: Oncology Product Name: LiPlaCis
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Smerud Medical Research
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 29, 2020
Details:
Oncology Venture has entered a definitive agreement, out-licensing two clinical pipeline assets, LiPlaCis® and 2X-111, to Smerud Medical Research International for further clinical and commercial development.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SCO-101,Taxane
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Innovation Fund Denmark
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Funding February 19, 2020
Details:
The grant of DKK 5 million from Innovation Fund Denmark is earmarked for the clinical phase II development of SCO-101 in metastatic pancreatic cancer.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
